Tasquinimod is primarily investigated for its potential in cancer treatment, particularly in prostate cancer. It functions as an immunomodulatory agent, targeting the tumor microenvironment to inhibit angiogenesis and metastasis. By modulating the immune response, it helps reduce the growth and spread of cancer cells. Additionally, it has shown promise in enhancing the efficacy of other cancer therapies when used in combination. Research is ongoing to explore its broader applications in treating other types of cancers and its role in improving patient outcomes.